Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial
Table 1
Baseline characteristics of placebo and statin patients.
Placebo
Statin
value
26
25
Age (years)
56 ± 9
51 ± 12
NS
Male gender (%)
73
84
NS
BMI (kg/m²)
28.70 ± 3.94
28.28 ± 5.12
NS
History
Smoking (%)
50.0
60.0
NS
Alcohol (%)
38.5
56.0
NS
Diabetes (%)
0.0
4.0
NS
Dyslipidemia (%)
3.9
12.0
NS
Respiratory characteristics
AHI (n/h)
45.47 ± 13.10
43.26 ± 19.19
NS
Mean SaO2 (%)
92.57 ± 1.44
92.70 ± 2.40
NS
SaO2 < 90% (%)
10.33 ± 13.20
11.66 ± 18.11
NS
Clinical BP
SBP (mmHg)
127.67 ± 15.27
127.78 ± 15.07
NS
DBP (mmHg)
79.02 ± 11.61
79.16 ± 11.60
NS
MAP (mmHg)
95.22 ± 11.93
95.37 ± 12.21
NS
HR (bpm)
63 ± 8
64 ± 10
NS
Biological parameters
Total cholesterol (g/L)
2.25 ± 0.64
2.46 ± 0.94
NS
LDL cholesterol (g/L)
1.41 ± 0.45
1.60 ± 0.67
NS
HDL cholesterol (g/L)
0.54 ± 0.23
0.74 ± 0.52*
0.011
Triglycerides (g/L)
1.55 ± 1.10
1.16 ± 0.59
NS
Data are mean ± SD or percentage. BMI, body mass index; SaO2, oxygen saturation; SaO2 < 90%, percentage of recording time spent at a SaO2 < 90%; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HR, heart rate. by Student or Mann-Whitney test. For qualitative data, a Chi-2 test or a Fisher test was performed. NS, not significant.
